NYSE: BSXBoston Scientific Corp Stock
$72.91+3.92 (+5.68%)
Updated Apr 24, 2024
Boston Scientific shares are trading... find out Why BSX Price Moved with a free WallStreetZen account
Why Price MovedBSX Price
$72.91
Fair Value Price
N/A
Market Cap
$106.97B
52 Week Low
$48.35
52 Week High
$74.39
P/E
67.51x
P/B
5.55x
P/S
5.9x
PEG
2x
Dividend Yield
N/A
Revenue
$14.24B
Earnings
$1.59B
Gross Margin
69.5%
Operating Margin
15.81%
Profit Margin
11%
Debt to Equity
0.81
Operating Cash Flow
$3B
Beta
0.9
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BSX Overview
Boston Scientific Corp manufactures medical devices used in interventional radiology, interventional cardiology, peripheral interventions, and neuromodulation. It is known primarily for the development of the Taxus Stent used to open clogged arteries. With the acquisition of Cameron Health in 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (the EMBLEM subcutaneous implantable defibrillator). Boston Scientific was founded in 1979 and is headquartered in Marlborough, MA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BSX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BSX ($72.91) is trading above its intrinsic value of $18.66, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BSX is poor value based on its earnings relative to its share price (67.51x), compared to the US market average (41.27x)
P/E vs Market Valuation
BSX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BSX due diligence checks available for Premium users.
Be the first to know about important BSX news, forecast changes, insider trades & much more!
BSX News
Valuation
BSX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
67.51x
Industry
30.46x
Market
41.27x
BSX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BSX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BSX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.55x
Industry
3.73x
BSX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BSX price to earnings growth (PEG)
For valuing profitable companies with growth potential
BSX is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
BSX's financial health
Profit margin
Revenue
$3.7B
Net Income
$505.0M
Profit Margin
13.6%
BSX's Earnings (EBIT) of $2.25B... subscribe to Premium to read more.
Interest Coverage Financials
BSX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$35.1B
Liabilities
$15.6B
Debt to equity
0.81
BSX's short-term assets ($6.51B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BSX's long-term liabilities ($10.67B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BSX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BSX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$957.0M
Investing
-$1.1B
Financing
$15.0M
BSX's operating cash flow ($2.50B)... subscribe to Premium to read more.
Debt Coverage Financials
BSX vs Medical Device Stocks
Boston Scientific Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.